Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 300

1.

Clinical and social determinants of antipsychotic polypharmacy for Chinese patients with schizophrenia.

Xiang YT, Weng YZ, Leung CM, Tang WK, Ungvari GS.

Pharmacopsychiatry. 2007 Mar;40(2):47-52.

PMID:
17447172
2.

Clinical and social correlates with the use of depot antipsychotic drugs in outpatients with schizophrenia in China.

Xiang YT, Weng YZ, Leung CM, Tang WK, Ungvari GS.

Int J Clin Pharmacol Ther. 2008 May;46(5):245-51.

PMID:
18538110
3.

Exploring the clinical and social determinants of prescribing anticholinergic medication for Chinese patients with schizophrenia.

Xiang YT, Weng YZ, Leung CM, Tang WK, Sandor UG.

Hum Psychopharmacol. 2007 Apr;22(3):173-80. Erratum in: Hum Psychopharmacol. 2007 Jun;22(4):255. Ungvari, Gabor Sandor [corrected to Sandor, Ungvari Gabor].

PMID:
17397098
4.

Clinical correlates of clozapine prescription for schizophrenia in China.

Xiang YT, Weng YZ, Leung CM, Tang WK, Ungvari GS.

Hum Psychopharmacol. 2007 Jan;22(1):17-25.

PMID:
17191268
5.

Clinical and social determinants of long-term use of benzodiazepines and its impact on quality of life of Chinese schizophrenia patients.

Xiang YT, Weng YZ, Leung CM, Tang WK, Ungvari GS.

Pharmacopsychiatry. 2007 Nov;40(6):269-74.

PMID:
18030651
6.

Clinical and social determinants of psychotropic drug prescription for schizophrenia outpatients in China.

Xiang YT, Weng YZ, Leung CM, Tang WK, Ungvari GS, Gerevich J.

Prog Neuropsychopharmacol Biol Psychiatry. 2007 Apr 13;31(3):756-60. Epub 2007 Jan 16.

PMID:
17289236
7.

Long-term use of mood stabilizers and its impact on the quality of life of chinese patients with schizophrenia.

Xiang YT, Weng YZ, Leung CM, Tang WK, Ungvari GS.

Clin Neuropharmacol. 2009 Jan-Feb;32(1):16-21. doi: 10.1097/WNF.0B013E31815D25B5.

PMID:
18978504
8.

Socio-demographic and clinical correlates of lifetime suicide attempts and their impact on quality of life in Chinese schizophrenia patients.

Xiang YT, Weng YZ, Leung CM, Tang WK, Ungvari GS.

J Psychiatr Res. 2008 May;42(6):495-502. Epub 2007 Jul 30.

PMID:
17663994
9.

Antipsychotic drug prescription for schizophrenia in East Asia: rationale for change.

Chong MY, Tan CH, Fujii S, Yang SY, Ungvari GS, Si T, Chung EK, Sim K, Tsang HY, Shinfuku N.

Psychiatry Clin Neurosci. 2004 Feb;58(1):61-7.

10.

Determinants of first- and second-generation antipsychotic drug use in clinically unstable patients with schizophrenia treated in four European countries.

Barbui C, Nosè M, Mazzi MA, Bindman J, Leese M, Schene A, Becker T, Angermeyer MC, Koeter M, Gray R, Tansella M.

Int Clin Psychopharmacol. 2006 Mar;21(2):73-9.

PMID:
16421457
11.

Determinants of antipsychotic polypharmacy in psychiatric inpatients: a prospective study.

Biancosino B, Barbui C, Marmai L, Donà S, Grassi L.

Int Clin Psychopharmacol. 2005 Nov;20(6):305-9. Erratum in: Int Clin Psychopharmacol. 2007 Mar;22(2):124. Donà, Silna [corrected to Donà, Silvia].

PMID:
16192838
12.

Antipsychotic polypharmacy in inpatients with schizophrenia in Asia (2001-2009).

Xiang YT, Wang CY, Si TM, Lee EH, He YL, Ungvari GS, Chiu HF, Yang SY, Chong MY, Tan CH, Kua EH, Fujii S, Sim K, Yong KH, Trivedi JK, Chung EK, Udomratn P, Chee KY, Sartorius N, Shinfuku N.

Pharmacopsychiatry. 2012 Jan;45(1):7-12. doi: 10.1055/s-0031-1286345. Epub 2011 Oct 11.

PMID:
21989602
13.

Prevalence, utilization patterns, and predictors of antipsychotic polypharmacy: experience in a multistate Medicaid population, 1998-2003.

Morrato EH, Dodd S, Oderda G, Haxby DG, Allen R, Valuck RJ.

Clin Ther. 2007 Jan;29(1):183-95.

PMID:
17379060
14.

Prevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients, 1998-2000.

Ganguly R, Kotzan JA, Miller LS, Kennedy K, Martin BC.

J Clin Psychiatry. 2004 Oct;65(10):1377-88.

PMID:
15491242
15.

High dose antipsychotic use in schizophrenia: findings of the REAP (research on east Asia psychotropic prescriptions) study.

Sim K, Su A, Leong JY, Yip K, Chong MY, Fujii S, Yang S, Ungvari GS, Si T, Chung EK, Tsang HY, Shinfuku N, Kua EH, Tan CH.

Pharmacopsychiatry. 2004 Jul;37(4):175-9.

PMID:
15467975
16.

Prescribing for inpatients with schizophrenia: an international multi-center comparative study.

Bitter I, Chou JC, Ungvari GS, Tang WK, Xiang Z, Iwanami A, Gaszner P.

Pharmacopsychiatry. 2003 Jul;36(4):143-9.

PMID:
12905100
17.

Switching antipsychotics in inpatient schizophrenia care: predictors and outcomes.

Weinmann S, Janssen B, Gaebel W.

J Clin Psychiatry. 2004 Aug;65(8):1099-105.

PMID:
15323596
18.

Factors associated with antipsychotic dosing in psychiatric inpatients: a prospective study.

Barbui C, Biancosino B, Esposito E, Marmai L, Donà S, Grassi L.

Int Clin Psychopharmacol. 2007 Jul;22(4):221-5.

PMID:
17519645
19.

Change of psychotropic drug prescription for schizophrenia in a psychiatric institution in Beijing, China between 1999 and 2008.

An FR, Xiang YT, Wang CY, Zhang GP, Chiu HF, Chan SS, Lee EH, Ungvari GS.

Int J Clin Pharmacol Ther. 2010 Apr;48(4):270-4.

PMID:
20353748
20.

Gender differences in sociodemographic and clinical characteristic and the quality of life of Chinese schizophrenia patients.

Xiang YT, Weng YZ, Leung CM, Tang WK, Chan SS, Wang CY, Han B, Ungvari GS.

Aust N Z J Psychiatry. 2010 May;44(5):450-5. doi: 10.3109/00048670903489858.

PMID:
20397787

Supplemental Content

Support Center